

## Product Datasheet

### CHIR-99021 monohydrochloride (orb1941068)

<b>Catalog Number</b>	orb1941068
<b>Category</b>	Small Molecules
<b>Description</b>	<p>A potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3<math>\beta</math> and GSK3<math>\alpha</math>, respectively; mimics Wnt signaling in preadipocytes, stabilizes free cytosolic beta-catenin and inhibits adipogenesis by blocking induction of C/EBP<math>\alpha</math> and PPAR<math>\gamma</math>; potentiates insulin activation of glucose transport and utilization in vitro and in vivo; also widely used for stem cell differentiation and naive stem cell generation.(In Vitro):Laduviglusib monohydrochloride inhibits human GSK-3<math>\beta</math> with Ki values of 9.8 nM. Laduviglusib monohydrochloride is a small organic molecule that inhibits GSK3<math>\alpha</math> and GSK3<math>\beta</math> by competing for their ATP-binding sites. In vitro kinase assays reveal that Laduviglusib monohydrochloride specifically inhibits GSK3<math>\beta</math> (IC50=<math>\sim</math>5 nM) and GSK3<math>\alpha</math> (IC50=<math>\sim</math>10 nM), with little effect on other kinases. In the presence of Laduviglusib monohydrochloride the viability of the ES-D3 cells is reduced by 24.7% at 2.5 <math>\mu</math>M, 56.3% at 5 <math>\mu</math>M, 61.9% at 7.5 <math>\mu</math>M and 69.2% at 10 <math>\mu</math>M Laduviglusib monohydrochloride with an IC50 of 4.9 <math>\mu</math>M.\n(In Vivo):In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) monohydrochloride rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. Laduviglusib (2 mg/kg) monohydrochloride given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib monohydrochloride treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib monohydrochloride treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h.</p>
<b>Target</b>	GSK-3
<b>Purity</b>	>98% (HPLC)
<b>MW</b>	501.7989
<b>Target Areas</b>	GSK-3

#### Biorbyt Ltd.

7 Signet Court, Swann Road  
Cambridge  
CB5 8LA  
United Kingdom

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: [+44 \(0\)1223 859353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

#### Biorbyt LLC

68 TW Alexander Drive  
Research Triangle Park  
Durham  
NC 27713  
United States

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

<b>Solubility (25°C)</b>	10 mM in DMSO
<b>CAS Number</b>	1797989-42-4
<b>Formula</b>	C <sub>22</sub> H <sub>19</sub> Cl <sub>3</sub> N <sub>8</sub>
<b>SMILES</b>	<chem>CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N.Cl</chem>
<b>Chemical Name</b>	3-Pyridinecarbonitrile, 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-, hydrochloride (1:1)
<b>Storage</b>	Storage temperature: -20°C. Stability: ≥ 2 years
<b>Note</b>	For research use only
<b>Expiration Date</b>	12 months from date of receipt.

**Biorbyt Ltd.**

7 Signet Court, Swann Road  
Cambridge  
CB5 8LA  
United Kingdom

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)

Phone: [+44 \(0\)1223 859353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)

**Biorbyt LLC**

68 TW Alexander Drive  
Research Triangle Park  
Durham  
NC 27713  
United States

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)

Phone: [+1 \(415\) 906-5211](tel:+1(415)906-5211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)